论文部分内容阅读
本刊曾在2011年第11期上刊登过一则有关多发性硬化症(MS)治疗药———抗CD52单抗alemtu-zumab(专利名:LemtradaTM)的Ⅲ期临床研究获得阳性结果的报道。Genzyme公司近日在第64届美国神经病学学会(AAN)年会上公布了本品在该项名
In this issue, we published a positive result in Phase III clinical studies on multiple sclerosis (MS), an anti-CD52 monoclonal antibody, alemtu-zumab (patent name: LemtradaTM) . Genzyme Inc. recently announced at the 64th annual meeting of the American College of Neurology (AAN) this product in the name